Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NGL Fine-ChemNSE:NGLFINE -0.23%79 EV-to-EBITDA is 19.49 as of Aug. 20, 2026, which is 33% above its 10-year median of 14.70. GuruFocus rates NSE:NGLFINE with a GF Score™ of 79/100 and a GF Value™ of ₹3,019.88 (Fairly Valued). The stock has 4 warning signs investors should review. Among 736 Drug Manufacturers companies, NGL Fine-Chem ranks worse than 66.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NGL Fine-Chem's enterprise value is ₹19,631 Mil.
NGL Fine-Chem's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹1,007 Mil. Therefore, NGL Fine-Chem's EV-to-EBITDA for today is 19.49.
The historical rank and industry rank for NGL Fine-Chem's EV-to-EBITDA or its related term are showing as below:
NSE:NGLFINE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.02 Med: 14.7 Max: 29.3
Current: 19.49
During the past 13 years, the highest EV-to-EBITDA of NGL Fine-Chem was 29.30. The lowest was 5.02. And the median was 14.70.
NSE:NGLFINE's EV-to-EBITDA is ranked worse than 66.03% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.305
vs NSE:NGLFINE: 19.49
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NGL Fine-Chem's PE Ratio (TTM) for today is calculated as:
NGL Fine-Chem's share price for today is ₹3033.30.
NGL Fine-Chem's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹92.590.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for NGL Fine-Chem's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: EV-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's EV-to-EBITDA falls into.
NGL Fine-Chem's current Enterprise Value is ₹19,631 Mil.
NGL Fine-Chem's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,007 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGL Fine-Chem (NSE:NGLFINE) has a EV-to-EBITDA of 19.49 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NGL Fine-Chem. This is 33% above median its historical median of 14.70. Over the past decade, NGL Fine-Chem's EV-to-EBITDA has ranged from 5.02 to 29.30. According to the industry distribution chart, NGL Fine-Chem ranks #486 out of 736 companies in the Drug Manufacturers industry, placing it in the top 66%.
Is NGL Fine-Chem's EV-to-EBITDA too high?
NGL Fine-Chem's current EV-to-EBITDA of 19.49 is 33% above median its 10-year median of 14.70. Over the past 10 years, this metric has ranged from a low of 5.02 to a high of 29.30. The Drug Manufacturers industry median EV-to-EBITDA is 13.31. NGL Fine-Chem's value of 19.49 is 46.5% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #486 out of 736 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's EV-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #486 out of 736 companies for EV-to-EBITDA. This places NGL Fine-Chem in the lower half of its industry. The industry median EV-to-EBITDA is 13.31. NGL Fine-Chem's value of 19.49 is 46.5% above this benchmark. Historically, NGL Fine-Chem's own EV-to-EBITDA has ranged from 5.02 to 29.30 over the past decade. While the company's 10-year median is 14.70 vs. the industry median of 13.31, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.31, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current EV-to-EBITDA of 19.49 is 46.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NGL Fine-Chem. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current EV-to-EBITDA is 19.49, which is 33% above median its own 10-year median of 14.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Fairly Valued. The stock's GF Value™ is ₹3,019.88, compared to a current price of ₹3,033.30 — trading 0.4% above its estimated fair value. The current EV-to-EBITDA is 19.49, which is 33% above median its 10-year median of 14.70 and 46.5% above the Drug Manufacturers industry median of 13.31. NGL Fine-Chem's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current EV-to-EBITDA is 19.49 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹3,033.30 is trading 0.4% above its estimated GF Value™ of ₹3,019.88.
GuruFocus considers NGL Fine-Chem to be Fairly Valued.
Key valuation signals for NSE:NGLFINE:
EV-to-EBITDA: 19.49 (33% above median its 10-year median of 14.70)
GF Value™: ₹3,019.88 vs. price of ₹3,033.30 (0.4% above fair value)
Industry Position: 46.5% above the Drug Manufacturers median (#486 of 736)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
79GF Score
Get the complete analysis for NSE:NGLFINE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
